Inflammatory Bowel Disease · Article 136

Infliximab or Cyclosporine: Which Rescue Therapy Should Be Used for Acute Severe UC?

ASUC rescue therapy requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

ASUC rescue therapy clinical reference — Related free clinical resource: First Principles of Gastroenterology and Hepatology.

ASUC rescue therapy: practical clinical approach

This page focuses on ASUC rescue therapy with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for ASUC rescue therapy

Clinical takeaway: For ASUC rescue therapy, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Infliximab and cyclosporine are both guideline-supported rescue therapies for steroid-refractory ASUC, and randomized evidence has not established a universal superiority of one over the other. Selection should consider prior anti-TNF or immunomodulator exposure, albumin, comorbidity, contraindications, center experience, monitoring burden and the intended maintenance strategy. Infliximab is often favored operationally because it can continue as maintenance therapy; cyclosporine can be highly effective when used by experienced teams and bridged to an appropriate maintenance agent.

Efficacy is broadly comparable

Head-to-head trials and long-term follow-up support both strategies. The choice is therefore often practical and patient-specific.

When infliximab is attractive

It is familiar in IBD practice, does not require drug-level renal/neurotoxicity monitoring like calcineurin inhibitors and can be continued for maintenance.

When cyclosporine is attractive

It can act rapidly and may be particularly useful in selected biologic-naive patients or when anti-TNF therapy is unsuitable. It requires experienced dosing and monitoring.

Albumin matters

Low albumin can increase infliximab clearance in ASUC; the 2025 ACG update notes consideration of dose intensification when albumin is very low.

Practical clinical algorithm

Confirm steroid failure by day 3.
Review prior biologic/immunomodulator exposure and contraindications.
Assess albumin, renal function, infection status and surgical readiness.
Choose infliximab or cyclosporine based on patient factors and center expertise.
Define the maintenance plan at the time rescue is chosen.
Monitor closely and proceed to surgery promptly if rescue fails.

Common mistakes to avoid

Treating rescue therapy as a reason to postpone necessary colectomy.
Starting cyclosporine without a maintenance/bridge plan.
Ignoring prior anti-TNF failure.
Using repeated sequential rescue agents routinely.
Assuming infliximab is always superior.

Trainee takeaway

The best rescue drug is the one that fits the patient’s prior therapy, physiology, maintenance plan and the center’s ability to use it safely—without delaying surgery.

Frequently asked questions

Are infliximab and cyclosporine equally effective?

Broadly, randomized comparative evidence has not shown clear universal superiority.

Can tofacitinib or upadacitinib replace standard rescue?

Current ACG guidance says evidence is insufficient for routine use after IV steroid failure or infliximab induction failure in ASUC.

Should surgery be consulted before rescue?

Yes. Surgical planning should occur in parallel, not after rescue fails.

References

1. Thomson ABR. Guideline-Based Management in Gastroenterology. CAPstone Academic Publishers; 2015.

2. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

3. Rubin DT, et al. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025;120:1187-1224.

4. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in severe ulcerative colitis refractory to intravenous steroids. Lancet. 2012;380:1909-1915.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions